Tolbutamide clinical trials
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses Tolbutamide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 31 May 1957 · ORINASE · NDA 010670 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2010 (1)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Pfizer (1) · Cognition Therapeutics (1) · Corcept Therapeutics (1) · Swedish Orphan Biovitrum (1) · Boehringer Ingelheim (1) · Eli Lilly and Company (1)
Often tested with
Tested in the same studies.
Metoprolol (2) · PF-06651600 (1) · Zervimesine (1) · Midazolam (1) · Pioglitazone (1) · Omeprazole (1) · Relacorilant (1) · Nitisinone (1)
Related medicines
As reviewed, each with the page that says it.
- One of Hypoglycemic Agents source
Studies
Open first, then newest update. How each study uses Tolbutamide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of TolbutamideCompletedPhase 1PfizerNCT05097716Written as TolbutamideHow we know
- Drug Interaction Study of CT1812 in Healthy VolunteersCompletedPhase 1Cognition TherapeuticsNCT03716427Written as tolbutamideHow we know
- A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or LymphomaTerminatedPhase 1Eli Lilly and CompanyNCT01185548Written as TolbutamideHow we know
- Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450sCompletedPhase 1Corcept TherapeuticsNCT03457597Written as TolbutamideHow we know
- A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy VolunteersCompletedPhase 1Swedish Orphan BiovitrumNCT03103568Written as TolbutamideHow we know
- Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected PatientsCompletedPhase 1Boehringer IngelheimNCT01525628Written as tolbutamideHow we know
Given beside what is tested · 8 — Tolbutamide is usual care or a partner of the new treatment
- Licorice Botanical Dietary Supplements - Metabolism and Safety in WomenCompletedPhase 1University of Illinois at ChicagoNCT03948243Written as Tolbutamide 250 mgHow we know
- Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)CompletedPhase 1Daiichi SankyoNCT03291288Written as TolbutamideHow we know
- A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of TucatinibCompletedPhase 1Seagen Inc.NCT03723395Written as tolbutamideHow we know
- A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 SubstratesCompletedPhase 1Janssen Research & Development, LLCNCT02211079Written as TolbutamideHow we know
- A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTSCompletedPhase 1Daiichi SankyoNCT02473627Written as TolbutamideHow we know
- Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT01218620Written as TolbutamideHow we know
- Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male VolunteersTerminatedPhase 1Boehringer IngelheimNCT02182401Written as TolbutamideHow we know
- AZD2066 Cocktail StudyCompletedPhase 1AstraZenecaNCT00930306Written as TolbutamideHow we know
Codes
What other systems call Tolbutamide · ClinicalTrials.gg INT008333
- MeSH (NLM) D014044TolbutamideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 982XCM1FOITOLBUTAMIDEConfirmed FDA, NLM, Wikidata
- RxNorm 10635Confirmed FDA, Wikidata
- Wikidata Q414275tolbutamideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66610TolbutamideOne source FDA
- DrugBank DB01124One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D014044 | Tolbutamide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 982XCM1FOI | TOLBUTAMIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 10635 | — | Confirmed FDA, Wikidata |
| Wikidata | Q414275 | tolbutamide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66610 | Tolbutamide | One source FDA |
| DrugBank | DB01124 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.